CMC Pharmaceuticals has been awarded a Sequential Phase II Small Business Innovation Research (SBIR) grant from the U.S. Defense Department’s (DoD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Threat Reduction Agency.   The award funds the continued development of a promising medical countermeasure (MCM) for nerve agents that contain a stable, fixed-dose combination formulation of atropine and scopolam...